Two companies originating within the Oxford University Innovation portfolio have announced significant funding rounds in close succession, together raising more than £375 million for work in quantum computing and antibody therapeutics.
The two financings are separate transactions with distinct investor bases, but taken together they illustrate the continuing flow of institutional and private capital into research commercialised out of the University of Oxford.
A £260m Series C for quantum computing
Oxford Quantum Circuits has closed a £260 million Series C. The company develops superconducting quantum computing technology, and its work is based on quantum research originating at the University of Oxford.
Quantum computing remains a long-duration investment theme. Rounds of this size indicate that investors are prepared to fund extended hardware development cycles rather than waiting for commercial validation.
A $115m Series A in antibody science
RQ Biotechnology has raised $115 million, approximately £85.5 million, in Series A financing. The company develops long-acting antibody therapies intended to protect vulnerable patients from infectious disease.
Its underlying science comes from University of Oxford research led by Professor Gavin Screaton, with the intellectual property licensed through Oxford University Innovation.
A pattern rather than an isolated event
Neither round should be read as decisive on its own. Read alongside other recent Oxford activity — including the Series C raised by AgriTech company Moa Technology and the acquisition of F1 Seed by Wild Bioscience — they suggest a functioning pipeline from university research through licensing to growth-stage capital.
For family offices and institutional allocators, the relevant question is less about individual companies than about access: whether exposure to this pipeline is best obtained through specialist managers, co-investment, or direct participation alongside established university-linked investors.
The commercialisation of university research, and the capital structures that support it, feature across the UKFOS Oxford 2026 programme.
UKFOS Editorial · 13 August 2026